Antidepressants for the negative symptoms of schizophrenia-Reference-Cited by-同舟云学术

Antidepressants for the negative symptoms of schizophrenia

Published:2006-07-19 Issue: Volume: Page:
ISSN:
Container-title:Cochrane Database of Systematic Reviews
language:
Short-container-title:

Author:

Rummel-Kluge Christine,Kissling Werner,Leucht Stefan

Publisher

John Wiley & Sons, Ltd

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005581.pub2/epdf/full

Reference184 articles.

1. A double-blind trial of amitriptyline-perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics;Collins;British Journal of Psychiatry,1967

2. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study;Hayashi;International Clinical Psychopharmacology,1997

3. Serotonin-dopamine antagonists in elderly schizophrenics;Yamawaki,1996

4. Improvement of schizophrenic negative symptoms by the addition of paroxetine to antipsychotics: a double-blind placebo-controlled study;Jockers-Scherübl,2004

5. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study;Jockers-Scherübl;International Clinical Psychopharmacology,2005

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects;Schizophrenia;2023-05-26

2. Use of Bupropion in the Management of Negative Symptom Schizophrenia: A Case Series;Cureus;2022-03-26

3. Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia;The World Journal of Biological Psychiatry;2022-02-01

4. Evidence-Based Treatment with Antipsychotics in Schizophrenia: S3-Guideline and Current References;NeuroPsychopharmacotherapy;2022

5. Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study;The Pharmacogenomics Journal;2021-04-06